

## PROTEOMICS: TECHNOLOGIES AND GLOBAL MARKETS



BIO034C  
May 2013

John Bergin  
*Project Analyst*

ISBN: 1-56965-403-4

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481  
866-285-7215, 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
Custom Reports:  
[carol.laverty@bccresearch.com](mailto:carol.laverty@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE	3
SCOPE AND FORMAT	3
METHODOLOGY	3
INFORMATION SOURCES	4
ANALYST'S CREDENTIALS	4
RELATED BCC REPORTS	4
BCC ONLINE SERVICES	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2017 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2017 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW	10
PROTEOMIC TECHNOLOGIES	10
<i>TABLE 1 ARRAY VERSUS LOAC BIOCHIPS</i>	11
<i>TABLE 2 SCOPE OF REPORT</i>	12
PROTEOMIC MARKET	12
<i>TABLE 3 GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2017 (\$ MILLIONS)</i>	13
<i>TABLE 4 GLOBAL PROTEOMIC MARKET BY PLATFORM, THROUGH 2017 (\$ MILLIONS)</i>	14
DRIVING FORCES FOR PROTEOMIC INDUSTRY GROWTH	15
<i>TABLE 5 PROTEOMIC INDUSTRY GROWTH DRIVERS</i>	15
PROTEOMIC INDUSTRY	16
<i>TABLE 6 BIOCHIP INDUSTRY COMPARISONS</i>	16
CHAPTER 4 PROTEOMIC TECHNOLOGIES	19
INTRODUCTION TO TECHNOLOGY PLATFORMS	19
<i>FIGURE 1 MASS SPECTROMETRY-BASED PROTEOMIC WORKFLOW</i>	19
<i>FIGURE 2 PROTEOMIC BIOCHIP AND ARRAY FORMATS</i>	21
MASS SPECTROMETRY-BASED PROTEOMIC TECHNOLOGIES	22
SAMPLE PREPARATION ASSAYS	22
TAGGING AND AFFINITY METHODS	23
MASS SPECTROMETRY INSTRUMENTS AND CONSUMABLES	23
<i>TABLE 7 MASS SPECTROMETER PLATFORMS</i>	25
BIOCHIP-BASED PROTEOMIC TECHNOLOGIES	25
<i>TABLE 8 BIOCHIP-BASED PROTEOMIC TECHNOLOGIES</i>	25
<i>TABLE 9 PLANAR-BASED VERSUS BEAD-BASED ARRAYS</i>	26
ADVANCES IN PROTEOMIC TECHNOLOGIES	27
<i>TABLE 10 TECHNICAL ADVANCES IN PROTEOMICS</i>	27

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 5 PROTEOMIC APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT	30
<i>TABLE 11 PROTEOMIC APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT</i>	30
TARGET DISCOVERY	30
LEAD IDENTIFICATION	32
LEAD OPTIMIZATION	33
PRECLINICAL STUDIES	33
CHAPTER 6 PROTEOMIC SCIENTIFIC INITIATIVES	35
<i>TABLE 12 LARGE-SCALE PROTEOMIC INITIATIVES</i>	35
CHAPTER 7 CLINICAL PROTEOMIC APPLICATIONS	39
<i>TABLE 13 STRATEGIES FOR OVERCOMING HIGH-ABUNDANCE PROTEINS IN CLINICAL SAMPLES</i>	39
CANCER APPLICATIONS	40
CANCER OVERVIEW	40
<i>TABLE 14 U.S. INCIDENCE OF SELECTED CANCERS, 2010</i>	40
BLADDER CANCER	41
<i>TABLE 15 STATUS OF ADVANCED BLADDER CANCER DIAGNOSTICS</i>	41
BREAST CANCER	43
Breast Cancer Screening	43
Prognosis and Pharmacogenetics Tests	43
<i>TABLE 16 U.S. ANNUAL BREAST CANCER TREATMENT DECISIONS BY CLASSIFICATION</i>	44
Breast Cancer MDx Platforms	45
<i>TABLE 17 BREAST CANCER MDX TECHNOLOGY PLATFORMS</i>	45
<i>TABLE 18 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS</i>	46
LUNG CANCER	50
<i>TABLE 19 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL-CELL LUNG CANCER (%)</i>	50
<i>TABLE 20 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS</i>	51
OVARIAN CANCER	55
<i>TABLE 21 EARLY SCREENING OVARIAN CANCER TESTS</i>	55
<i>TABLE 22 STATUS OF ADVANCED OVARIAN CANCER DIAGNOSTICS</i>	56
PROSTATE CANCER	58
<i>TABLE 23 STATUS OF ADVANCED PROSTATE CANCER DIAGNOSTICS</i>	59
THYROID CANCER	62
GENERAL CANCER	62
INFECTIOUS DISEASE APPLICATIONS	62
NEUROLOGICAL APPLICATIONS	63
ALZHEIMER'S DISEASE	63
<i>TABLE 24 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES</i>	63
<i>TABLE 25 STATUS OF ALZHEIMER'S DISEASE ADVANCED DIAGNOSTIC TESTS</i>	64
SCHIZOPHRENIA	65
IMMUNE DISEASE APPLICATIONS	66
HUMAN LEUKOCYTE ANTIGEN TYPING TESTS	66
<i>TABLE 26 HUMAN LEUKOCYTE ANTIGEN TESTING MARKET</i>	67
ALLERGY AND AUTOIMMUNE DISEASE	69
CHAPTER 8 PROTEOMIC INDUSTRY	71

<b>TOPIC</b>	<b>PAGE NO.</b>
INDUSTRY ACQUISITIONS	71
<i>TABLE 27 PROTEOMIC INDUSTRY ACQUISITIONS, 2010-2012</i>	71
INDUSTRY STRATEGIC ALLIANCES	73
<i>TABLE 28 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2010-2012</i>	73
MASS SPECTROMETRY INDUSTRY	77
<i>TABLE 29 FIRST-TIER MASS SPECTROMETRY COMPANIES</i>	77
<i>TABLE 30 SECOND-TIER MASS SPECTROMETRY COMPANIES</i>	78
PROTEOMIC CHROMATOGRAPHY INDUSTRY	79
<i>FIGURE 3 CHROMATOGRAPHY RESINS IN MS WORKFLOW</i>	79
<i>TABLE 31 GLOBAL HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES</i>	80
<i>TABLE 32 JAPANESE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES</i>	81
PROTEOMIC-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY	82
<i>TABLE 33 GLOBAL PHARMACEUTICAL RESEARCH AND DEVELOPMENT OUTSOURCING (\$ BILLIONS)</i>	82
<i>TABLE 34 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY</i>	83
PROTEOMIC BIOCHIP INDUSTRY	84
PEPTIDE MICROARRAY INDUSTRY	84
<i>TABLE 35 KEY PEPTIDE MICROARRAY COMPANIES</i>	85
ANTIBODY MICROARRAY INDUSTRY	86
<i>TABLE 36 KEY ANTIBODY MICROARRAY COMPANIES</i>	86
CHINA BIOCHIP INDUSTRY	87
<i>TABLE 37 CHINESE BIOCHIP INDUSTRY</i>	88
LAB-ON-A-CHIP PROTEOMIC INDUSTRY	89
<i>TABLE 38 LAB-ON-A-CHIP COMPETITOR LANDSCAPE</i>	90
ANTIBODY REAGENT INDUSTRY	91
<i>TABLE 39 ANTIBODY REAGENT MARKET, 2012 (%)</i>	92
MULTIPLEX PROTEIN DIAGNOSTICS INDUSTRY	92
<i>TABLE 40 MULTIPLEX PROTEIN IN VITRO DIAGNOSTIC COMPANIES</i>	93
CHAPTER 9 PROTEOMIC MARKETS	97
DRIVING FORCES OF PROTEOMIC INDUSTRY GROWTH	97
<i>TABLE 41 PROTEOMIC INDUSTRY GROWTH DRIVERS</i>	97
GLOBAL PROTEOMIC MARKETS	98
PROTEOMIC MARKET SUMMARY	98
<i>TABLE 42 GLOBAL PROTEOMIC MARKET BY PLATFORM, THROUGH 2017 (\$ MILLIONS)</i>	98
<i>TABLE 43 GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2017 (\$ MILLIONS)</i>	99
PROTEOMIC RESEARCH MARKETS	101
<i>TABLE 44 GLOBAL PROTEOMIC RESEARCH PRODUCT MARKET BY PLATFORM, THROUGH 2017 (\$ MILLIONS)</i>	102
<i>TABLE 45 GLOBAL PROTEOMIC RESEARCH MARKET BY BIOCHIP PLATFORM, THROUGH 2017 (\$ MILLIONS)</i>	102
PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT MARKETS	103
<i>TABLE 46 GLOBAL PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT PRODUCT MARKET BY PLATFORM, THROUGH 2017 (\$ MILLIONS)</i>	103

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 47 GLOBAL PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT BIOCHIP MARKET BY PLATFORM, THROUGH 2017 (\$ MILLIONS)</i>	104
PROTEOMIC DIAGNOSTIC MARKETS	105
<i>TABLE 48 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY PLATFORM, THROUGH 2017 (\$ MILLIONS)</i>	105
<i>TABLE 49 GLOBAL BIOCHIP DIAGNOSTIC MARKET BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	106
<i>TABLE 50 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY DISEASE TYPE, THROUGH 2017 (\$ MILLIONS)</i>	108
<i>TABLE 51 STATUS OF PROTEOMIC-BASED DIAGNOSTICS FOR CARDIOLOGY, IMMUNE SYSTEM AND NEUROLOGY APPLICATIONS</i>	109
<i>TABLE 52 GLOBAL PROTEOMIC CANCER DIAGNOSTIC PRODUCT MARKET BY INDICATION, THROUGH 2017 (\$ MILLIONS)</i>	110
<i>TABLE 53 STATUS OF PROTEOMIC-BASED DIAGNOSTICS FOR CANCER APPLICATIONS</i>	111
MASS SPECTROMETRY-BASED PROTEOMIC MARKETS	112
<i>TABLE 54 GLOBAL MASS SPECTROMETRY MARKET BY PRODUCT TYPE, THROUGH 2017 (\$ MILLIONS)</i>	112
<i>TABLE 55 GLOBAL MASS SPECTROMETRY MARKET BY END USER INDUSTRY, THROUGH 2017 (\$ MILLIONS)</i>	113
<i>TABLE 56 GLOBAL MASS SPECTROMETRY INSTRUMENT MARKET BY TECHNIQUE, THROUGH 2017 (\$ MILLIONS)</i>	115
<i>TABLE 57 GLOBAL MASS SPECTROMETRY CONSUMABLE MARKET BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	116
BIOCHIP-BASED PROTEOMIC MARKETS	117
<i>TABLE 58 GLOBAL PROTEOMIC BIOCHIP MARKET BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	117
<i>TABLE 59 GLOBAL PROTEOMIC ARRAY MARKET BY TYPE, THROUGH 2017 (\$ MILLIONS)</i>	118
<i>TABLE 60 GLOBAL PROTEOMIC BIOCHIP MARKET BY END USER, THROUGH 2017 (\$ MILLIONS)</i>	118
<i>TABLE 61 GLOBAL PROTEOMIC ARRAY MARKET BY END USE, THROUGH 2017 (\$ MILLIONS)</i>	119
<i>TABLE 62 GLOBAL PROTEOMIC LAB-ON-A-CHIP MARKET BY END USE, THROUGH 2017 (\$ MILLIONS)</i>	121
PROTEOMIC GEOGRAPHIC MARKETS	124
<i>TABLE 63 GLOBAL PROTEOMIC MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	124
<i>TABLE 64 GLOBAL PROTEOMIC DIAGNOSTIC MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	125
CHAPTER 10 PROTEOMIC PATENTS	127
BIOCHIP PATENTS	127
PROTEIN ARRAY PATENTS	127
<i>TABLE 65 ARRAY-RELATED PROTEOMIC PATENTS BY REGION, 2002-2012</i>	127
LAB-ON-A-CHIP PATENTS	128
<i>TABLE 66 LAB-ON-A-CHIP-RELATED PROTEOMIC PATENTS BY REGION, 2002-2012</i>	128
MASS SPECTROMETRY PATENTS	128
<i>TABLE 67 MASS SPECTROMETRY-RELATED PROTEOMIC PATENTS BY REGION, 2002-2012</i>	129
CHAPTER 11 COMPANY PROFILES	131

TOPIC	PAGE NO.
ABLYNX NV	131
ACTIVIOMICS LTD.	131
ACTIVX BIOSCIENCES INC.	132
ADNEXUS THERAPEUTICS	132
ADVANCED PROTEOME THERAPEUTICS INC.	132
AGILENT TECHNOLOGIES INC.	133
APPLIED PROTEOMICS	134
AYOXXA BIOSYSTEMS GMBH	134
BIODESIX	135
BIOGNOSYS AG	136
BIOPROXIMITY LLC	136
BIO-RAD LABORATORIES INC.	137
BIOSYSTEMS INTERNATIONAL SAS	137
BRUKER CORPORATION	138
CALIBRANT BIOSYSTEMS INC.	138
CAMBRIDGE PROTEIN ARRAYS LTD.	139
CAPRION PROTEOMICS	139
CAPROTEC BIOANALYTICS GMBH	140
CRELUX GMBH	140
CRYSTALGENOMICS INC.	141
DANAHER CORP.	142
DIASSESS	142
DIGILAB INC.	143
DNANO SYSTEMS LLC	143
DURIN TECHNOLOGIES INC.	144
DVS SCIENCES INC.	144
EVOTEC AG	144
GENERAL ELECTRIC CO.	145
GLAXOSMITHKLINE PLC	145
GL SCIENCES INC.	146
GWC TECHNOLOGIES	146
IMMUNOVIA AB	147
IMTAKT CORPORATION	147
INTEGRATED DIAGNOSTICS	148
IRIS INTERNATIONAL INC.	148
LEAP TECHNOLOGIES INC.	149
LIFE TECHNOLOGIES INC.	149
LUMINEX CORPORATION	150
MERCK KGAA	150
MICROLYTIC APS	151
MRM PROTEOMICS INC.	151
MOSAIQUES DIAGNOSTICS AND THERAPEUTICS AG	152
MYRIAD GENETICS INC.	152
NEXTGEN SCIENCES INC.	152
OLINK BIOSCIENCE	153
ONCOPLEX DX	153
OPKO HEALTH INC.	154

<b>TOPIC</b>	<b>PAGE NO.</b>
PERKIN ELMER INC.	154
PFIZER INC.	155
PHENOMENEX	156
PHYLOGICA LTD.	156
PRESSURE BIOSCIENCES INC.	157
PRONOTA NV	157
PROTEA BIOSCIENCES INC.	158
PROTEOME SCIENCES	159
PROTEOMICS INTERNATIONAL PTY LTD	159
PROVISTA DIAGNOSTICS INC.	160
QIAGEN NV	160
QUANTERIX INC.	161
QUEST DIAGNOSTICS INC.	161
REPLIGEN CORPORATION	162
SAMDI TECH INC.	162
SHIMADZU CORPORATION	163
SHISEIDO COMPANY LTD.	163
SHOWA DENKO KK	164
SIGMA ALDRICH	164
SINGULEX INC.	165
SISCAPA ASSAY TECHNOLOGIES	165
SOMALOGIC INC.	165
<i>TABLE 68 SOMALOGIC PROTEOMIC METHODS</i>	166
SPHERE FLUIDICS LTD.	166
SPOTON CLINICAL DIAGNOSTICS LTD.	167
SYNAGEVA BIOPHARMA	167
TALKING20 INC.	168
<i>TABLE 69 PERSONALIZED PROTEOMIC COMPANIES</i>	168
THERANOSTICS HEALTH	169
THERMO FISHER SCIENTIFIC INC.	169
<i>TABLE 70 THERMO FISHER SCIENTIFIC RECENT ACQUISITIONS</i>	170
THORNE DIAGNOSTICS INC.	171
TOSOH CORPORATION	171
UNIVERSAL BIOSENSORS LTD.	171
<i>TABLE 71 UNIVERSAL BIOSENSORS DIAGNOSTIC PIPELINE</i>	171
VERMILLION INC.	172
VIRAL GENETICS INC.	173
WATERS CORP.	173
XENCOR INC.	174
YMC CO. LTD.	174

## LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2017 (\$ MILLIONS)	7
TABLE 1 ARRAY VERSUS LOAC BIOCHIPS	11
TABLE 2 SCOPE OF REPORT	12
TABLE 3 GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2017 (\$ MILLIONS)	13
TABLE 4 GLOBAL PROTEOMIC MARKET BY PLATFORM, THROUGH 2017 (\$ MILLIONS)	14
TABLE 5 PROTEOMIC INDUSTRY GROWTH DRIVERS	15
TABLE 6 BIOCHIP INDUSTRY COMPARISONS	16
TABLE 7 MASS SPECTROMETER PLATFORMS	25
TABLE 8 BIOCHIP-BASED PROTEOMIC TECHNOLOGIES	25
TABLE 9 PLANAR-BASED VERSUS BEAD-BASED ARRAYS	26
TABLE 10 TECHNICAL ADVANCES IN PROTEOMICS	27
TABLE 11 PROTEOMIC APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT	30
TABLE 12 LARGE-SCALE PROTEOMIC INITIATIVES	35
TABLE 13 STRATEGIES FOR OVERCOMING HIGH-ABUNDANCE PROTEINS IN CLINICAL SAMPLES	39
TABLE 14 U.S. INCIDENCE OF SELECTED CANCERS, 2010	40
TABLE 15 STATUS OF ADVANCED BLADDER CANCER DIAGNOSTICS	41
TABLE 16 U.S. ANNUAL BREAST CANCER TREATMENT DECISIONS BY CLASSIFICATION	44
TABLE 17 BREAST CANCER MDX TECHNOLOGY PLATFORMS	45
TABLE 18 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS	46
TABLE 19 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL-CELL LUNG CANCER (%)	50
TABLE 20 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS	51
TABLE 21 EARLY SCREENING OVARIAN CANCER TESTS	55
TABLE 22 STATUS OF ADVANCED OVARIAN CANCER DIAGNOSTICS	56
TABLE 23 STATUS OF ADVANCED PROSTATE CANCER DIAGNOSTICS	59
TABLE 24 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES	63
TABLE 25 STATUS OF ALZHEIMER'S DISEASE ADVANCED DIAGNOSTIC TESTS	64
TABLE 26 HUMAN LEUKOCYTE ANTIGEN TESTING MARKET	67
TABLE 27 PROTEOMIC INDUSTRY ACQUISITIONS, 2010-2012	71
TABLE 28 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2010-2012	73
TABLE 29 FIRST-TIER MASS SPECTROMETRY COMPANIES	77
TABLE 30 SECOND-TIER MASS SPECTROMETRY COMPANIES	78
TABLE 31 GLOBAL HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES	80
TABLE 32 JAPANESE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES	81
TABLE 33 GLOBAL PHARMACEUTICAL RESEARCH AND DEVELOPMENT OUTSOURCING (\$ BILLIONS)	82
TABLE 34 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY	83
TABLE 35 KEY PEPTIDE MICROARRAY COMPANIES	85
TABLE 36 KEY ANTIBODY MICROARRAY COMPANIES	86
TABLE 37 CHINESE BIOCHIP INDUSTRY	88
TABLE 38 LAB-ON-A-CHIP COMPETITOR LANDSCAPE	90
TABLE 39 ANTIBODY REAGENT MARKET, 2012 (%)	92
TABLE 40 MULTIPLEX PROTEIN IN VITRO DIAGNOSTIC COMPANIES	93



<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 41 PROTEOMIC INDUSTRY GROWTH DRIVERS	97
TABLE 42 GLOBAL PROTEOMIC MARKET BY PLATFORM, THROUGH 2017 (\$ MILLIONS)	98
TABLE 43 GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2017 (\$ MILLIONS)	99
TABLE 44 GLOBAL PROTEOMIC RESEARCH PRODUCT MARKET BY PLATFORM, THROUGH 2017 (\$ MILLIONS)	102
TABLE 45 GLOBAL PROTEOMIC RESEARCH MARKET BY BIOCHIP PLATFORM, THROUGH 2017 (\$ MILLIONS)	102
TABLE 46 GLOBAL PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT PRODUCT MARKET BY PLATFORM, THROUGH 2017 (\$ MILLIONS)	103
TABLE 47 GLOBAL PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT BIOCHIP MARKET BY PLATFORM, THROUGH 2017 (\$ MILLIONS)	104
TABLE 48 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY PLATFORM, THROUGH 2017 (\$ MILLIONS)	105
TABLE 49 GLOBAL BIOCHIP DIAGNOSTIC MARKET BY TYPE, THROUGH 2017 (\$ MILLIONS)	106
TABLE 50 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY DISEASE TYPE, THROUGH 2017 (\$ MILLIONS)	108
TABLE 51 STATUS OF PROTEOMIC-BASED DIAGNOSTICS FOR CARDIOLOGY, IMMUNE SYSTEM AND NEUROLOGY APPLICATIONS	109
TABLE 52 GLOBAL PROTEOMIC CANCER DIAGNOSTIC PRODUCT MARKET BY INDICATION, THROUGH 2017 (\$ MILLIONS)	110
TABLE 53 STATUS OF PROTEOMIC-BASED DIAGNOSTICS FOR CANCER APPLICATIONS	111
TABLE 54 GLOBAL MASS SPECTROMETRY MARKET BY PRODUCT TYPE, THROUGH 2017 (\$ MILLIONS)	112
TABLE 55 GLOBAL MASS SPECTROMETRY MARKET BY END USER INDUSTRY, THROUGH 2017 (\$ MILLIONS)	113
TABLE 56 GLOBAL MASS SPECTROMETRY INSTRUMENT MARKET BY TECHNIQUE, THROUGH 2017 (\$ MILLIONS)	115
TABLE 57 GLOBAL MASS SPECTROMETRY CONSUMABLE MARKET BY TYPE, THROUGH 2017 (\$ MILLIONS)	116
TABLE 58 GLOBAL PROTEOMIC BIOCHIP MARKET BY TYPE, THROUGH 2017 (\$ MILLIONS)	117
TABLE 59 GLOBAL PROTEOMIC ARRAY MARKET BY TYPE, THROUGH 2017 (\$ MILLIONS)	118
TABLE 60 GLOBAL PROTEOMIC BIOCHIP MARKET BY END USER, THROUGH 2017 (\$ MILLIONS)	118
TABLE 61 GLOBAL PROTEOMIC ARRAY MARKET BY END USE, THROUGH 2017 (\$ MILLIONS)	119
TABLE 62 GLOBAL PROTEOMIC LAB-ON-A-CHIP MARKET BY END USE, THROUGH 2017 (\$ MILLIONS)	121
TABLE 63 GLOBAL PROTEOMIC MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)	124
TABLE 64 GLOBAL PROTEOMIC DIAGNOSTIC MARKET BY REGION, THROUGH 2017 (\$ MILLIONS)	125
TABLE 65 ARRAY-RELATED PROTEOMIC PATENTS BY REGION, 2002-2012	127
TABLE 66 LAB-ON-A-CHIP-RELATED PROTEOMIC PATENTS BY REGION, 2002-2012	128
TABLE 67 MASS SPECTROMETRY-RELATED PROTEOMIC PATENTS BY REGION, 2002-2012	129
TABLE 68 SOMALOGIC PROTEOMIC METHODS	166
TABLE 69 PERSONALIZED PROTEOMIC COMPANIES	168
TABLE 70 THERMO FISHER SCIENTIFIC RECENT ACQUISITIONS	170

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 71 UNIVERSAL BIOSENSORS DIAGNOSTIC PIPELINE	171

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2017 (\$ MILLIONS)	7
FIGURE 1 MASS SPECTROMETRY-BASED PROTEOMIC WORKFLOW	19
FIGURE 2 PROTEOMIC BIOCHIP AND ARRAY FORMATS	21
FIGURE 3 CHROMATOGRAPHY RESINS IN MS WORKFLOW	79